Danwang Medical Technology Shanghai Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Danwang Medical Technology Shanghai Co., Ltd. - overview
Established
2019
Location
Hangzhou, Zhejiang, China
Primary Industry
Healthcare
About
Established in 2019 and based in Shanghai, China, D1med operates an organoid technology developer that focuses on tumor diagnosis and treatment field. It cooperates with Merck China, Fudan University, Shanghai Jiao Tong University, and Shanghai Pulmonary Hospital. The founder, Guoqiang Guoqiang graduated from Fudan University and has published his research work in Cell Stem Cell and CancerResearch. In December 2024, the company closed a strategic investment led by new investor Sinowisdom.
The company's business can be categorized into tumor personalized precision therapy, drug company R&D services, Patient in the Lab organ-like disease model library, and IVD reagents and automation equipment. It has also developed organoid service platforms for new drug research and development companies, such as Next Generation Diagnostics of Organoid, Next Generation Drug Diagnostics Platform of Organoid, and Next Generation Culture of Organoid. Danwang Medical Technology Shanghai Co. , Ltd.
generates revenue by clinical development and application of organoid technology.
Current Investors
Co-Win Ventures, Yushan Partners, Delian Capital
Primary Industry
Healthcare
Sub Industries
Healthcare, Oncology/Cancer Treatment, Diagnostic Equipment, Pharmaceutical Research & Development
Company Stage
Series A
Total Amount Raised
Subscriber access only
Danwang Medical Technology Shanghai Co., Ltd. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer & General Manager | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.